DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)
ID: 355995Type: Posted
Overview

Buyer

Office of National Drug Control Policy (ONDCP)

Award Range

$0 - $3M

Eligible Applicants

Nonprofits Without 501(c)(3) Status

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355995

Additional Information

https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=113144
Timeline
    Description

    The Office of National Drug Control Policy is offering a federal grant opportunity titled "DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)." This program aims to enhance the capacity of the prevention workforce and community coalitions to implement evidence-based interventions aimed at preventing substance use among adolescents, particularly during the critical ages of 12 to 19. The initiative recognizes the importance of early prevention efforts in reducing the likelihood of substance use disorders later in life, thereby promoting health and social benefits. The total estimated funding for this grant is $2,500,000, with a maximum award ceiling of $2,500,000 and no minimum award amount. Interested applicants, specifically nonprofits without 501(c)(3) status, must submit their proposals by September 16, 2024, and can reach out to the Grants.gov Customer Support at support@grants.gov for further assistance.

    Point(s) of Contact
    support@grants.gov
    Files
    No associated files provided.
    Similar Opportunities
    Drug-Free Communities (DFC) Support Program - Competing Continuation (Year 6)
    Active
    Centers for Disease Control - NCIPC
    The Centers for Disease Control and Prevention (CDC), through the National Center for Injury Prevention and Control (NCIPC), is forecasting the availability of grants under the Drug-Free Communities (DFC) Support Program for Fiscal Year 2025. This program aims to establish and strengthen collaborations among community coalitions to prevent and reduce substance use among youth, specifically targeting individuals aged 18 and younger. Eligible applicants include community-based coalitions that have previously received DFC funding and are either resuming after a lapse or entering a second five-year funding cycle. The total estimated funding for this opportunity is $12.5 million, with individual awards ranging from $0 to $125,000, and approximately 100 awards expected to be made. Interested parties should note that applications must be submitted electronically by March 31, 2025, with an anticipated award date of August 29, 2025. For further inquiries, applicants can contact Brandis Belser at dfcnofo@cdc.gov.
    Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement grant titled "Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose." This funding opportunity aims to support research that evaluates prevention strategies aimed at reducing nonfatal and fatal overdoses, particularly among populations at higher risk due to social determinants of health. The initiative is crucial for addressing the ongoing public health crisis related to drug overdoses and substance use disorders, especially among youth. The estimated total program funding is $4.9 million, with an award ceiling of $700,000 and an expected seven awards to be made. Interested applicants must submit their proposals electronically by December 2, 2024, and can direct inquiries to Candis M. Hunter at ncipcerpo@cdc.gov.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    Emergency Department Substance Use Surveillance System
    Active
    Office of National Drug Control Policy
    The Office of National Drug Control Policy (ONDCP) is offering a cooperative agreement for the Emergency Department Substance Use Surveillance System, aimed at enhancing drug early warning indicators through expanded testing methodologies. The project focuses on re-testing previously collected urine samples to identify a broader range of drugs, including emerging substances like xylazine and fentanyl, and aims to analyze these results in conjunction with electronic health records to improve drug exposure surveillance across various populations. This initiative is crucial for reinforcing best practices and standardizing testing in emergency departments nationwide. Interested applicants, specifically private institutions of higher education, should note that the funding ceiling is set at $150,000, with a submission deadline of September 17, 2024. For further inquiries, contact the Grants.gov Customer Support at 1-800-518-4726.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Strategic Prevention Framework – Partnerships for Success for Communities, Local Governments, Universities, Colleges, and Tribes/Tribal Organizations
    Active
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is offering a federal grant opportunity titled "Strategic Prevention Framework – Partnerships for Success for Communities, Local Governments, Universities, Colleges, and Tribes/Tribal Organizations." This program aims to reduce the onset and progression of substance misuse and related issues by enhancing community-based prevention and mental health promotion services, thereby strengthening local prevention providers' capacity to implement evidence-based programs. With an estimated total program funding of $15,500,000 and an expected 41 awards, the grant has a funding ceiling of $375,000 and is open for applications for FY 2024 and FY 2025, with deadlines on February 26, 2024, and February 21, 2025, respectively. Interested applicants can reach out to the Office of Financial Resources at SAMHSA via email at FOACSAP@samhsa.hhs.gov for further information.
    NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the P50 Research Center of Excellence Grant Program to support innovative research in substance use and addiction. This program aims to establish multidisciplinary research centers that not only advance scientific knowledge but also serve as national resources for education and outreach within the drug abuse research community. The initiative encourages applications that focus on integrated themes rather than incremental work, with a budget limit of $10 million over five years and a maximum of 25% of direct costs allocated to pilot projects. Interested applicants should note that the submission process requires adherence to specific guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP), and key deadlines extend until November 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Sober Truth on Preventing Underage Drinking Act (STOP Act) Grant Program
    Active
    Substance Abuse and Mental Health Services Adminis
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is forecasting the availability of the Sober Truth on Preventing Underage Drinking Act (STOP Act) Grant Program, aimed at preventing and reducing alcohol use among youth and young adults aged 12-20 across the United States. This grant program seeks to address various factors related to underage drinking, including social norms, enforcement efforts, and penalties, while building on strategic plans developed under previous Drug Free Communities (DFC) grants. With an estimated total program funding of $749,000 and an expected 12 awards, eligible applicants include domestic public and private nonprofit entities that are current or former DFC Support Program recipients. Interested parties can reach out to Jerry Campbell at (240) 276-0117 or via email at CSAP.DPP@samhsa.hhs.gov for further information, with the synopsis expected to be posted on November 15, 2024.
    Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.